Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: A multinational, 24-week, randomized, clinical trial.

ABSTRACT:

Aims/introduction

Asian patients represent a large portion of the global population with type 2 diabetes mellitus, but are underrepresented in trials of glucose-lowering therapies. The present randomized, phase III, placebo-controlled, double-blind, 24-week study evaluated the dipeptidyl peptidase-4 inhibitor, linagliptin, as monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus.

Materials and methods

Patients who were treatment naïve or had been treated with one oral antidiabetes drug were randomized to either linagliptin 5 mg daily or a placebo after washout. The primary end-point was a change from baseline in glycated hemoglobin after 24 weeks.

Results

A total of 300 Asian (87% Chinese) patients with type 2 diabetes mellitus were rando

SUBMITTER: Chen Y 

PROVIDER: S-EPMC4627547 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature